Inorganic Chemistry
Article
synthesis reported in the literature.52 A solution of 4-
(trifluoromethyl)benzenesulfonyl chloride (0.500 g, 2.044 mmol) in
CH2Cl2 (20 mL) was added to a solution of ethylendiamine (1.228 g,
20.43 mmol) in CH2Cl2 (200 mL) at 0 °C. The mixture was stirred at
room temperature for 16 h and then extracted with 1 M HCl (3 × 100
mL). The combined aqueous phases were basified to pH 10 with
NaOH and extracted with CH2Cl2 (3 × 100 mL). The organic
extracts were dried with Na2SO4 and concentrated, affording 1 as a
CONCLUSIONS
■
In this work, we have presented two ligands containing a
sulfonamide pendant and their Mn2+ complexes, which were
conceived as potential pH-responsive MRI agents. In the case
of [Mn(DPASAm)]−, protonation of the sulfonamide group
was observed close to the physiologically relevant pH range.
Complex protonation provokes a 2.3-fold increase in 1H
relaxivity from r1p = 3.8 mM−1 s−1 at pH 9.0 to r1p = 8.9 mM−1
s−1 at pH 4.0 (20 MHz, 25 °C). Relaxometric and
potentiometric studies are in good mutual agreement, showing
that the complex is perfectly stable in the pH range of 4−10.
The X-ray structure of the [Mn(DPASAm)]− complex
evidences coordination of the deprotonated sulphonamide N
atom, as well as the presence of a coordinated water molecule.
The relaxometric characterization showed that the relaxivity
increase observed upon complex protonation is related to the
coordination of a second water molecule.
1
white solid (0.502 g, 1.871 mmol, 92% yield). H NMR (300 MHz,
CDCl3) δ 8.01 (d, J = 8.2 Hz, 2H), 7.79 (d, J = 8.2 Hz, 2H), 3.00 (t, J
= 5.6 Hz, 2H), 2.93−2.71 (m, 2H). 19F NMR (282 MHz, CDCl3) δ
−63.1. MS (ESI+): m/z calcd for C9H12F3N2O2S [M + H]+: 269.06.
Found: 269.06.
Diethyl 6,6′-(((2-((4-(trifluoromethyl)phenyl)sulfonamido)-
ethyl)azanediyl)bis(methylene))dipicolinate (2). A solution of
ethyl 6-(chloromethyl)picolinate (0.2981 g, 1.493 mmol) in dry
CH3CN (3 mL) was added dropwise to a solution of compound 1
(0.2001 g, 0.7459 mmol) containing K2CO3 (0.2577 g, 1.864 mmol)
in dry CH3CN (35 mL). A catalytic amount of KI was added and the
mixture was purged with an argon flow while stirred at room
temperature for 6 days. The reaction mixture was filtered and the
filtrate was evaporated to dryness in vacuo. The product was purified
by MPLC on neutral alumina (CH2Cl2:MeOH 90:10 (v:v)) and
isolated as a yellow oil (0.2752 g, 0.4628 mmol, 62% yield). 1H NMR
(300 MHz, CDCl3) δ 8.04 (m, 2H), 7.97 (m, 2H), 7.45−7.80 (m,
The [Mn(NO2ASAm)]− complex is also protonated,
although the sulfonamide group was found to be considerably
less basic than in [Mn(DPASAm)]− (pKa = 5.5 and 6.4,
respectively). This can be attributed to a stronger Mn−
Nsulfonamide interaction in [Mn(NO2ASAm)]−, because of the
lower coordination number of the metal ion. Besides the lower
pKa, [Mn(NO2ASAm)]− is characterized by a lower condi-
tional stability than [Mn(DPASAm)]−, associated with a high
basicity of the macrocyclic structure. As a result, the
[Mn(NO2ASAm)]− complex dissociates at a relatively high
pH. These results highlight that ligand basicity plays a key role
in the stability of potential Mn2+ MRI contrast agents, so that
this issue should be carefully considered for ligand design.
Overall, the results reported in this paper provide a proof-of-
concept on the design of pH-responsive Mn2+ MRI probes
based on reversible binding of sulfonamide groups, although
further probe optimization to improve kinetic inertness is
required for practical applications, as the [Mn(DPASAm)]−
complex dissociates very quickly when challenged with an
excess of Zn2+ (see Figure S35 in the Supporting Information).
Another aspect that must be considered is the biodistribution
of the probe, because the intensity of the MRI signal will be
dependent both on the protonation state of the complex and
the local concentration of the agent.
3
6H), 7.11 (b, 1H), 4.51 (q, J = 7.1 Hz, 4H), 3.89 (s, 4H), 3.14 (b,
3
2H), 2.84 (m, 2H), 1.46 (t, J = 7.1 Hz, 6H). 19F NMR (282 MHz,
CDCl3) δ −63.0. 13C NMR (75.5 MHz, CDCl3) δ 165.0, 159.4,
147.6, 144.4, 137.4, 133.5 (1JC−F = 32.2 Hz), 127.5, 126.3, 125.9,
123.5, 61.8, 59.5, 53.8, 41.3, 14.2. MS(ESI+): m/z calcd for
C27H29F3N4NaO6S [M + Na]+: 617.17. Found: 617.17.
H3DPASAm. Compound 2 (0.2501 g, 0.4206 mmol) was dissolved
in 6 M HCl (20 mL) and the mixture was heated at 55 °C for 16 h.
The acid was evaporated, water (3 mL) was added and evaporated
again twice to remove most of the HCl. The ligand was isolated by
1
filtration as a white solid (0.1435 g, 0.2528 mmol, 60% yield). H
NMR (500 MHz, D2O, pH 14) δ 7.50−7.65 (m, 8H), 7.18 (m, 2H),
3.60 (s, 4H), 2.63 (m, 2H), 2.33 (m, 2H). 19F NMR (376 MHz, D2O,
pH 14) δ −62.5. 13C NMR (126 MHz, D2O, pH 14) δ 172.7, 168.4,
157.6, 152.5, 146.5, 138.1, 126.5, 125.7, 125.3, 122.2, 60.0, 55.6, 42.2.
HRMS (ESI−): m/z calcd for C23H20F3N4O6S [M−H]−: 537.1061.
Found: 537.1064. Elemental analysis: calculated for C23H21F3N4O6S·
0.8HCl: C: 48.84; H: 3.69; N: 9.54. Found: C: 48.66; H: 3.87; N:
9.87. IR (ATR, ν[cm−1]): 1738 ν(CO), 1575 ν(CN), 1356,
1322, 1164 ν(SO).
N-(2-Bromoethyl)-4-(trifluoromethyl)benzenesulfonamide
(3). The synthesis followed the procedure reported for closely related
compounds.53 2-Bromoethan-1-amine hydrobromide (0.4702 g, 2.295
mmol, 1 equiv) and triethylamine (0.640 mL, 4.5918 mmol, 2 equiv)
were dissolved in CH2Cl2 (15 mL). 4-(Trifluoromethyl)-
benzenesulfonyl chloride (0.5614 g, 2.295 mmol, 1 equiv) dissolved
in CH2Cl2 (2 mL) was added dropwise to the solution while stirring
at room temperature. The yellowish solution was stirred for 24 h. The
solution was washed with 1 M HCl (3 × 15 mL) followed by brine
(10 mL). The organic layer was dried using Na2SO4, filtered and the
solvent was evaporated. The white solid was washed with acidified
water (pH 5; 2 × 10 mL) and dried (0.6154 g, 1.853 mmol, 81%
yield). 1H NMR (300 MHz, CDCl3): δ 8.02 (d, 3J = 8.5 Hz, 2H), 7.81
EXPERIMENTAL SECTION
■
Materials and Methods. Ethyl 6-(chloromethyl)picolinate51 was
prepared following the literature methods. Di-tert-butyl 2,2′-(1,4,7-
triazonane-1,4-diyl)diacetate (NO2AtBu) was purchased from
CheMatech (Dijon, France). All other reagents were purchased
from Aldrich Chemical Co.
High-resolution electrospray-ionization time-of-flight ESI-TOF
mass spectra were recorded using a LC-Q-q-TOF Applied Biosystems
QSTAR Elite spectrometer in positive and negative mode. Mass
spectra recorded using electron impact ionization were recorded with
a Thermo MAT95XP instrument. Elemental analyses were accom-
plished on a ThermoQuest Flash EA 1112 elemental analyzer.
Medium performance liquid chromatography (MPLC) was per-
formed using a Puriflash XS 420 instrument equipped with a reverse-
phase Puriflash 15C18HP column (60 Å, spherical 15 μm, 20 g) and
UV-DAD detection at 210 and 254 nm, and operating at a flow rate of
10 mL/min. Aqueous solutions were lyophilized using a Telstar
3
(d, J = 8.5 Hz, 2H), 5.24 (b, 1H), 3.43 (m, 4H). 19F NMR (282
MHz, CDCl3): −63.1. 13C NMR (75.5 MHz, CDCl3): δ 143.5, 127.5,
126.5 (2JC−F = 3.8 Hz), 44.6, 31.5. MS (EI, 70 eV): m/z calcd for
C9H9BrF3NO2S [M+]: 330.9. Found: 330.9. Elemental analysis:
Calculated for C9H9BrF3NO2S: C: 32.55; H: 2.73; N: 4.22; S: 9.65.
Found: C: 33.07; H: 2.62; N: 3.93; S: 9.54.
1
Cryodos-80 apparatus. H, 13C, and 19F NMR spectra of the ligands
2,2′-(7-(2-((4-(Trifluoromethyl)phenyl) sulfonamido)ethyl)-
1,4,7-triazonane-1,4-diyl)diacetate (4). Di-tert-Butyl 2,2′-(1,4,7-
triazacyclononane-1,4-diyl)diacetate (0.1999 g, 0.5592 mmol, 1
equiv) was dissolved in dry CH3CN (10 mL) and K2CO3 (0.1932
g, 1.398 mmol) was added under argon. The mixture was stirred at
room temperature and compound 3 (0.1857 g, 0.5591 mmol, 1 equiv)
and their precursors were recorded at 298 K, using Bruker AVANCE
III 300 or Bruker Avance 500 spectrometers. 19F chemical shifts were
referenced by using sodium triflate on a D2O solvent (δ 75.6 ppm).
N-(2-Aminoethyl)-4-(trifluoromethyl)benzenesulfonamide
(1). This compound was prepared using a slight modification of the
H
Inorg. Chem. XXXX, XXX, XXX−XXX